'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations

@article{Tran2017FinalCP,
  title={'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations},
  author={Eric Tran and Paul F. Robbins and Steven A Rosenberg},
  journal={Nature Immunology},
  year={2017},
  volume={18},
  pages={255-262}
}
Effective clinical cancer immunotherapies, such as administration of the cytokine IL-2, adoptive cell transfer (ACT) and the recent success of blockade of the checkpoint modulators CTLA-4 and PD-1, have been developed without clear identification of the immunogenic targets expressed by human cancers in vivo. Immunotherapy of patients with cancer through the use of ACT with autologous lymphocytes has provided an opportunity to directly investigate the antigen recognition of lymphocytes that… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 58 CITATIONS, ESTIMATED 75% COVERAGE

A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice

  • Cancer Immunology, Immunotherapy
  • 2018
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Liquid biopsy for lung cancer immunotherapy

  • Oncology letters
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2017
2019

CITATION STATISTICS

  • 1 Highly Influenced Citations

  • Averaged 19 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 77 REFERENCES

Isolation of T cell receptors reactive with tumor neoantigens from tumor infiltrating lymphocytes based on CD 137 expression

M. R. Parkhurst
  • Clin . Cancer Res
  • 2016

Prospective identification of neoantigenspecific lymphocytes in the peripheral blood of melanoma patients

A. Gros
  • Nat . Med .
  • 2016

T - cell transfer therapy targeting mutated KRAS in cancer

E. Tran
  • N . Engl . J . Med .
  • 2016